• Explore /
  • Poster
  • / Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial.

Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial.

Abstract Poster

Authors

null

Benoit Samson

Hopital Charles-LeMoyne

Benoit Samson , Christophe Tournigand , Werner Scheithauer , Gérard Lledo , Frédéric Viret , Thierry André , Jean François Ramée , Nicole Tubiana-Mathieu , Jérôme Dauba , Olivier Dupuis , Yves Rinaldi , Nathalie Aucoin , Ahmed Khalil , Jean Latreille , Christophe Louvet , David Brusquant , Franck Bonnetain , Benoist Chibaudel , Aimery De Gramont , May Mabro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00265824

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr448)

DOI

10.1200/jco.2013.31.4_suppl.448

Abstract #

448

Poster Bd #

C4

Abstract Disclosures

Similar Posters

First Author: Christophe Tournigand

First Author: Benoist Chibaudel

First Author: Amelie Anota

First Author: Stefano Cascinu